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Abstract
Sanglifehrin A (SFA) is a cyclophilin-binding immunosuppressant but the immunobiology of action is poorly understood. We
and others have reported that SFA inhibits IL-12 production and antigen uptake in dendritic cells (DC) and exhibits lower
activity against lymphocytes. Here we show that SFA suppresses DC chemokine production and migration. Gene expression
analysis and subsequent protein level confirmation revealed that SFA suppressed CCL5, CCL17, CCL19, CXCL9 and CXCL10
expression in human monocyte-derived DC (moDC). A systems biology analysis, Onto Express, confirmed that SFA interferes
with chemokine-chemokine receptor gene expression with the highest impact. Direct comparison with the related agent
cyclosporine A (CsA) and dexamethasone indicated that SFA uniquely suppresses moDC chemokine expression.
Competitive experiments with a 100-fold molar excess of CsA and with N-Methyl-Val-4-cyclosporin, representing a
nonimmunosuppressive derivative of CsA indicated chemokine suppression through a cyclophilin-A independent pathway.
Functional assays confirmed reduced migration of CD4+ Tcells and moDCs to supernatant of SFA-exposed moDCs. Vice
versa, SFA-exposed moDC exhibited reduced migration against CCL19. Moreover, SFA suppressed expression of the
ectoenzyme CD38 that was reported to regulate DC migration and cytokine production. These results identify SFA as a DC
chemokine and migration inhibitor and provide novel insight into the immunobiology of SFA.
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Introduction
The immunophilin-binding agents cyclosporine A (CsA), FK506
and rapamycin represent potent immunosuppressive agents that
have revolutionized bone marrow and solid organ transplantation
as well as treatment of autoimmune diseases. Sanglifehrin A (SFA)
is a novel immunophilin-binding immunosuppressive drug isolated
from the actinomycetes strain Streptomyces A92-308110 exhibit-
ing high affinity binding to Cyclophilin A, but unknown
mechanism of action [1–4]. SFA does not affect the calcineurin
phosphatase or the mammalian target of rapamycin and it does
not inhibit purine or pyrimidine de novo synthesis [5]. Crystal
structure analysis of SFA in complex with cyclophilin A indicated
that the effector domain of SFA exhibits a chemical and three-
dimensional structure very different from CsA suggesting different
immunosuppressive action [6].
In contrast to CsA, the immunobiology of SFA is not well
understood. Previous reports demonstrated that SFA is different
from known immunosuppressive agent [5,7]. SFA is approximately
15–35-fold less potent than CsA at inhibiting T cell proliferation in
mouse and human MLR cultures [5]. In contrast to CsA and
FK506, SFA does not inhibit TCR-induced anergy [8]. Similarly to
rapamycin, SFA blocks IL-2 dependent proliferation in T cells [5].
Different groups have reported that SFA exerts suppressive
effects on human and mouse DC. SFA suppresses antigen uptake,
IL-12 and IL-18 production of DC in vitro and in vivo but it does
not inhibit DC differentiation and surface costimulatory molecule
expression [9–12].
DCs are professional antigen presenting cells that play a central
role in the initiation and modulation of innate and adaptive
immunity [13–17]. DC attract effector cells through different
chemokines that are critical for the coordination of the sequential
interaction of immediate effector cells, such as neutrophils and
natural killer cells and the delayed activation of antigen-specific B
and T lymphocytes [18–19]. Immunophilin-binding immunosup-
pressive agents, especially rapamycin, and to a lesser extent, CsA,
have been reported to target key functions of DC [13,20].
Rapamycin has been demonstrated to inhibit functional matura-
tion of DC and to promote their tolerogenicity in different animal
models [21–24].
In an experimental transplant model, SFA monotherapy did not
suppress acute organ allograft rejection supporting the hypothesis
that it does not represent a primary T cell inhibitor [11].
Interestingly, in combination with CsA, SFA efficiently promoted
long-term allograft survival [11]. Furthermore, in a chronic
allograft rejection model [11], addition of SFA to CsA-treated
recipients markedly inhibited chronic rejection compared to
animals receiving high dose CsA monotherapy, suggesting that
SFA exerted unique immunobiological effects different from
inhibition of calcineurin phosphatases.
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18406Current knowledge indicates that SFA represents a novel class
of immunophilin-binding metabolite both with respect to chemical
structure and functional activity [5–6,9–11]. There is a paucity of
knowledge about the immunobiological effects of SFA since each
study focused on selected functions or selected aspects with
professional antigen presenting cells being either directly or
indirectly involved. Systematic studies investigating the effects of
SFA are completely lacking.
In this report we describe the results of the first systematic
analysis of the immunobiological effects of the novel immunophil-
in-binding agent SFA on human monocyte-derived DC (moDC)
using a combination of genome-wide expression profiling with
subsequent confirmation on the protein level and functional in
vitro and in vivo assays. Results indicate that SFA represents a
novel DC chemokine and migration inhibitor.
Results
Sanglifehrin A blocks chemokine gene expression in
human moDCs
To systematically identify specific gene expression changes by
SFA, we compared human moDCs cultured in the presence of
either vehicle or drug. Human DCs were generated by differenti-
ation of monocytes with GM-CSF and IL-4 for five days. On day 5
human moDCs were either treated with 1 mM SFA or vehicle for
1 hour followed by 12 h LPS stimulation. The RNA of SFA vs.
vehicle-treated human moDCs was analysed by whole genome
Oligo Microarray. The Microarray data showed 260 significantly
regulated genes . 190 genes are significantly down regulated and 70
genes are up-regulated. The complete data are deposited in the
Gene Expression Omnibus database (http://www.ncbi.nlm.nih.
gov/geo/) with the GSE15956 accession number.
Pathway analysis of SFA vs. vehicle differentially
expressed genes
We analyzed the gene expression changes with PathwayExpress
from OntoExpress (http://vortex.cs.wayne.edu/ontoexpress/) to
get information about the biological functions [25]. Cytokine-
cytokine-receptor interaction, MAPKinase-, JAK/STAT-signal-
ling pathway and complement and coagulation cascades are the
functional groups containing the largest number of identified
proteins (Figure 1). The highest impact factor with 39.8 was found
with respect to cytokine-cytokine-receptor interactions. Analysis of
the cytokine pathway subfamilies revealed that SFA interfered
most frequently with the chemokine subfamily. Seven out of eleven
significantly regulated cytokines were chemokines (Table 1).
SFA suppresses CCL5, CCL17, CCL19, CXCL9 and CXCL10
production by human moDCs at the protein level
To confirm chemokine suppression by SFA in moDCs, we
analysed protein expression by ELISA. Short-term treatment (4 h)
Figure 1. SFA inhibits cytokine-cytokine receptor interactions. Human moDCs were treated with 1 mM SFA or vehicle for 1 hour and total
RNA was prepared after 12 h stimulation with 1 mg/mL LPS. The cDNA were labelled with Cy3- and Cy5-fluorescent dyes for microarray hybridization.
Chart summarizes the results of the pathway impact analysis. Numbers indicate the impact factor. The impact factor is calculated based on the
normalized fold of gene expression change, the number and amount of perturbation of genes downstream from it and the proportion of
differentially regulated genes in the respective pathway [25].
doi:10.1371/journal.pone.0018406.g001
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suppression of CCL5, CCL17, CXCL9 and CXCL10 production
(Figure 2 A, B, D, E). 100 nM SFA inhibited 84% of CCL19
production compared with vehicle-exposed controls (Figure 2C).
The up-regulation of CCL1 gene expression could not be
confirmed at the protein level (Figure 2 F). CCL26 expression
was below the detection limit of the ELISA (data not shown).
Rapid dose dependent moDC chemokine suppression
through SFA
Having established that short-term SFA treatment of moDC
significantly inhibited chemokine gene and protein expression we
next analysed the potency of SFA to suppress CCL5, CCL17 and
CCL19 in moDC. Administration of 50 nM SFA for 4 h resulted
in .80% CCL5 suppression (Figure 3 A), and 100 nm SFA
resulted in .70–90% CCL17 and CCL19 suppression (Figure 3
B, C).
Unique chemokine inhibition by SFA in comparison to
CsA and dexamethasone
Both, SFA and CsA bind with high affinity to cyclophilin in cells
[5]. Dexamethasone is a synthetic member of the glucocorticoid
class of steroid hormones and represents a prototypic immuno-
suppressive agent. 100 nM CsA and dexamethasone only
moderately affected CCL5, CCL17, CCL19, CXCL9 and
CXCL10 production by moDC (Figure 4 A–E). In contrast,
100 nM SFA inhibited CCL5, CCL17, and CCL19 production in
moDCs (Fig. 4 A–C). In contrast to SFA, CsA did not exhibit dose
dependent effects on CCL5, CCL17 and CCL19 expression up to
suprapharmacological doses of 10 mM . These experiments
suggested that SFA is a novel pleiotropic DC chemokine inhibitor
exhibiting a unique inhibitory profile when compared to the
related cyclophilin-bnding agent CsA and dexamethasone.
SFA inhibits chemokine production in moDCs in a
cyclophilin-A independent manner
To address the question whether SFA’s inhibitory activity on
chemokine expression is dependent on cyclophilin A binding, we
performed competitive experiments with a 100-fold molar excess of
CsA (10 mM). CsA has been described to potently inhibit the
binding of SFA to cyclophilin A [5] and we have found that CsA, in
contrast to SFA, did not abrogate CCL5, CCL17 and CCL19
production in moDCs. moDCs were preincubated for 1 hour with
10 mM CsA in order to saturate cylophilin binding sites. Whereas
even 10 mM CsA did not exert major effects on CCL19 production
in human moDC, addition of 100 nM SFA one hourlater markedly
inhibited CCL19 expression (Figure 5A). Similar results were
obtained with respect to CCL5 and CCL17 expression (Figure 5A).
These results indicated that chemokine suppression by SFA is
independent on cyclophilin A binding since binding of CsA to
cyclophilin A did not abrogate or impair the activity of SFA.
Interestingly, we observed that a combination of suprapharmaco-
logical doses of CsA with low doses of SFA consistently improved to
some extent the suppressive activity of SFA (Figure 5A). These data
might indicate that preincubation with CsA can possibly alter the
binding stochiometry of SFA to other immunophilins/target
molecules resulting in different immunosuppressive activity. How-
ever, since competitive experiments with CsA exhibited technical
limitations, especially the fact that CsA itself exerts immunosup-
pressive activity, we performed additional experiments with a
cyclophilin-binding non-immunosuppressive derivative of CsA, 4-
Cs that potently inhibits the binding of SFA to cyclophilin A [5].
The results indicated that addition of 4-Cs to moDC cultures did
not abrogate the suppressive activity of SFA (Figure 5B) suggesting
that DC chemokine suppression by SFA was independent of
cyclophilin binding.
Inhibition of moDC and CD4
+ T cell migration through
supernatant from SFA-exposed moDC
To confirm the functional relevance of SFA’s inhibition of
moDC chemokine expression we analysed CD4
+ T cell migration
and moDC migration towards supernatant from SFA-exposed
maturing moDCs and vehicle-exposed controls (Figure 6 A). To
eliminate any possibility of a direct influence of SFA on migration,
we added 1 mM SFA to the supernatant of vehicle-treated moDCs
and included these ‘‘SFA carry over controls’’ in the experiments.
These experiments revealed significant inhibition of both moDC
migration and, independently, CD4
+ T cell migration towards
supernatant from maturating, SFA-exposed moDCs (Figure 6).
SFA inhibits moDC migration towards CCL19 in a CCR7
independent manner
Given the fact that SFA efficiently inhibited chemokine
production by human moDCs we next questioned whether SFA
also directly inhibits moDC migration of maturing DCs (Figure 7
A). The capacity of SFA-treated LPS-matured human moDCs to
migrate towards CCL19 was evaluated in an in vitro migration
assay. In contrast to vehicle-treated moDC, SFA strongly
suppressed moDC migration towards CCL19 (Figure 7 A). Since
maturing DCs express the CCL19 ligand CCR7 that directs
migration of DC towards lymph nodes, we analysed CCR7
expression after SFA treatment (Figure 7 B, C). Interestingly, SFA
administration did not interfere with CCR7 up-regulation
indicating that SFA’s inhibitory effects on moDC migration were
CCR7-independent.
SFA inhibits the expression of multifunctional molecule
CD38
CD38 is an ectoenzyme and signalling receptor and was
reported to represent a novel human DC marker [26–27]. CD38 is
important for innate and adaptive immune responses by regulating
DC migration and pro-inflammatory cytokine expression [26–27].
Table 1. SFA-regulated genes in the cytokine-cytokine
receptor pathway.
systematic
name human ligand coefficient p.value Iods
*
CCL1 I-309 2.47 3.66E-07 7.36
CCL17 TARC 22.41 4.89E-09 9.76
CCL19 MIP-3b, ELC, exodus-3 23.61 4.61E-07 7.14
CCL26 Eotaxin-3 1.58 9.72E-07 6.40
CCL5 RANTES 22.92 1.78E-09 11.8
CXCL10 IP-10 21.27 7.6183E-05 1.88
CXCL9 MIG 22.96 6.92E-08 8.94
EBI3 23.08 3.81E-08 9.47
IL1R2 2.84 3.78E-08 9.48
TNFRSF14 22.11 3.28E-07 7.47
TNFRSF4 21.54 1.07E-06 6.31
*lods (log odds ratio for differential expression given an expectation of 1%
regulated genes on the array.
doi:10.1371/journal.pone.0018406.t001
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gene expression (coefficient 22.20949714, p=1.06*10
207). Given
the fact that SFA efficiently inhibited moDC migration in a
CCR7-independent manner and previous reports demonstrated
that SFA can abrogate IL-12 production in human DCs [10–11]
we questioned whether SFA is able to suppress surface CD38
expression on maturing human moDCs. Flow cytometry analysis
with CD38 mAb indicated that SFA caused a significant inhibition
of CD38 expression compared to controls and CD38 expression
decreased dose dependent after SFA-treatment (Figure 7 D).
Interestingly, in contrast to SFA, CsA did not suppress CD38
expression (Figure 7 D).
Figure 2. Rapid suppression of moDC chemokine production by SFA. Human moDCs were generated in the presence of GM-CSF and IL-4.
100 nM SFA or drug vehicle were added 4 h before stimulation with 100 ng/mL LPS. 12 hours later the supernatant was collected. CCL5 (A), CCL17
(B), CCL19 (C), CXCL9 (D), CXCL10 (E) and CCL1 (F) were analyzed by ELISA. The results are representative of n=6 (A,D), n=7 (E, F), n=8 (C), and n=11
(B) independent experiments (Mean 6 SEM). **p,0.01, *p,0.05 versus vehicle.
doi:10.1371/journal.pone.0018406.g002
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To investigate the in vivo activity of SFA on DC migration we
used the FITC-skin-painting model [28]. We treated animals in
vivo with SFA and studied the migration of skin resident CD11c+
DC to the inguinal lymph node. Resident DCs were mobilized by
FITC-painting of the shaved abdomen. We created a time course
of percentage changes in DC numbers in the inguinal lymph node
after FITC-painting. The percentage numbers of DC peaked at
24 h and then decreased. Animals received two i.p. injections of
SFA, CsA (10 mg/kg/day) or vehicle 24 hours before and on the
day of FITC-skin-painting. Inguinal lymph nodes were prepared
and migratory CD11
+FITC
+ skin DC quantified after 24 h by
flow cytometry (Fig. 8 A, B).
Discussion
Sanglifehrins represent novel immunosuppressive agents that
have been reported to suppress key functions of DCs [9–11]. We
and others have reported that SFA inhibits bioactive IL-12p70
production, macropinocytosis as well as receptor-mediated
endocytosis in human and murine DCs. Transplant experiments
indicated that addition of SFA to CsA efficiently suppresses graft
arteriosclerosis in comparison to CsA monotherapy suggesting that
SFA may represent a novel class of immunophilin-binding agents
[11].
However, a disadvantage of previous studies is the fact that they
have focused on selected molecules or selected functional aspects
thereby restricting the possibility to discover novel mechanisms of
action. Accordingly, the aim of the present study was to use a
systematic genome-wide approach in order to reveal novel
immunobiological effects of SFA on human DC. Secondly,
identification of molecules being most specifically suppressed by
SFA in comparison to the related molecule CsA may help to
elucidate the mechanism of action.
The results presented here indicate that SFA impairs DC-
mediated immunity in a so far unrecognized manner that is DC
chemokine expression and migration. Importantly, SFA’s inhibitory
effects can be demonstrated on two different functional levels such
as direct chemokine expression inhibition and subsequent impaired
attraction of CD4 helper T cells as wells as DC migration inhibition
towards recombinant CCL19. Accordingly, we have found that
SFA, in contrast to CsA, does not only inhibit mRNA and protein
Figure 3. Dose-dependent suppression of CCL5, CCL17 and CCL19 in moDCs by SFA. Human moDC were exposed on day 5 with 10,
50 100, 250 and 500 nM of SFA and 4 hours later stimulated with 100 ng/mL LPS. CCL5 (A), CCL7 (B) and CCL19 (C) production were analyzed after
12 h stimulation by ELISA. Mean (6 SEM) of n=3 (A) and n=4 (B, C) independent experiments.
doi:10.1371/journal.pone.0018406.g003
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and CCL19 but additionally suppresses CD38 mRNA and DC
surface expression. Thus, SFA’s effects on DC are unique in direct
comparison to the related cyclophilin-binding immunosuppressant
CsA. The latter results provide a rationale for the explanation of
reduced migration of SFA-exposed moDCs against recombinant
CCL19.CD38hasbeenreportedtoberequiredforthemigrationof
mature DC against recombinant CCL19 [29].
Furthermore, CD38 inhibition by SFA provides additional
insight into recent reports demonstrating SFA’s capacity to
abrogate bioactive IL-12 production in vitro and in vivo. CD38
has been shown to be functionally involved in IL-12 production
and IL-12 secretion has been demonstrated to be restored upon
CD38 ligation by agonistic anti-CD38 mAbs [26–27].
However, it is difficult to assess the specific role of CCL19
inhibition because SFA exerts pleiotropic effects both on chemokine
Figure 4. moDC chemokine suppression by SFA is unique in direct comparison to CsA and dexamethasone. Human moDC were
exposed to 100 nM SFA, CsA, dexamethasone or vehicle. After 4 h moDCs were stimulated with LPS (100 ng/ml) and CCL5, CCL17, CCL19, CXCL9,
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suppression in moDC by SFA may represent only one possible
explanation for reduced DC migration but the results do not
provide formal evidence for a direct link between CD38 and
reduced chemokine expression or responsiveness. Notably, besides
migration, CCL19/CCl21 chemokines have been correlated with
Figure 5. moDC chemokine suppression by SFA is independent of cylophilin A binding. To analyze whether DC chemokine suppression
by SFA is dependent on cyclophilin A binding competitive experiments with a 100-fold molar excess of CsA (A) and with a 10-fold molar excess of a
cyclophilin-binding nonimmunosuppressive derivative of CsA, 4_Cs (B) were performed. 4-Cs has been reported to efficiently inhibit SFA cyclophilin A
binding [5]. Human moDC were pre-exposed to 10 mM CSA and 1 hour later to 100 nM SFA (A). With respect to 4-Cs, moDC were pre-exposed to
2500 nM 4-Cs and 1 hour later to 250 nM SFA (B). After 4 hours, moDCs were stimulated with LPS (100 ng/ml) and DC chemokine production were
analyzed after 12 h by ELISA. In the presence of a 100-fold molar excess of CsA or a 10-fold molar excess of 4-Cs, SFA’s DC chemokine inhibitory
activity was not abrogated. In contrast, 10 mM CSA did not inhibit CCL5 (F) or CCL17 (G) moDC production and only moderately inhibited CCL19 (H)
expression. 4-Cs did not inhibit CCL5, CCL17 or CCL19 production. Mean (6 SEM) of n=3–6 independent experiments. **p,0.01, *p,0.05 versus
vehicle.
doi:10.1371/journal.pone.0018406.g005
Figure 6. Supernatant of SFA-exposed moDC induces reduced migration of activated moDC and CD4+ T cells. moDCs were generated
in the presence of GM-CSF and IL-4 and activated for 12 h with LPS. CD4 T cells were isolated by microbead-sorting and activated for 16 h with CD3/
CD28 mAbs. DC supernatant from SFA- or vehicle-exposed moDCs was harvested 12 h after LPS activation and added to the lower chamber of the
transwell. The ‘‘SFA carry over control’’ consisted of supernatant of control-treated moDCs+1 mM SFA. Migration of cells was quantitated by flow
cytometry. (A) Activated moDCs were inserted in the upper chamber of the transwell and migration was analysed after 4 h. (B) Activated CD4
+-T cells
were set in the upper chamber of the transwell and migration was analysed after 4 h. The spontaneous migration of cells was subtracted from the




PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e18406autoimmunity and immune suppression indicating an important
additional role balacing immunity and tolerance [30–31].
SFA’s effects on CCL5, CCL17, CCL19 and CD38 expression
are likely to be independent of cyclophilin-binding since
preincubation with a 100-fold molar excess of CsA did not
abrogate SFA’s inhibitory effects. These findings are in agreement
with Zenke et al. [5], who demonstrated that SFA’s activity in the
MLR is not abrogated in the presence of a 10-fold molar excess of
the cyclophilin-binding nonimmunosuppressive derivative, 4-Cs.
These findings provided additional insight into SFA’s effects to
inhibit chronic graft vasculopathy in CsA-treated recipients [11].
Chronic graft vasculopathy is characterized by continuous intimal
proliferation and infiltration of leukocytes [32]. The infiltration
and activation of leukocytes is mediated by chemokines that are
believed to play a critical role in the immunopathology of this
process [33–34]. Suppression of DC chemokine expression and
DC migration by SFA is likely to promote SFA’s capacity to
inhibit graft vasculopathy.
In conclusion, this first systematic genome-wide study revealed a
novel anti-inflammatory mode of action of SFA being different
from the related agent CsA. The suppressive activity of SFA with
regard to DC chemokine expression and migration in addition to
its inhibitory effects on DC antigen uptake and DC bioactive IL-
12 production identifies this immunophilin-binding agent as a
novel partner for combination with potent T-cell inhibitors.
Furthermore, with respect to the development of novel cell
migration inhibitors targeting either chemokine receptors, selectin
receptors or integrin receptors [35], SFA seems to represent an
attractive combination partner to potentiate the anti-inflammatory
activity of these novel agents. Since this study was focused on the
systematic analysis of SFA’s effects on human moDCs, further
studies are necessary to analyse the effects of SFA on chemokine
expression in T and B lymphocytes.
Materials and Methods
Ethics statement
The in vitro studies of human blood samples were approved by
the ethic study board of the University Hospital Gießen (File Nr
05/00) and the animal experiments were approved by the animal
ethics review board of the Regierungspra ¨sidium Gießen (File GI
20/8 Nr 49/2006).
Figure 7. SFA suppresses moDC migration to CCL19 in a CCR7 independent manner and inhibits CD38 expression. Human moDCs
were exposed to SFA, CsA or vehicle and matured for 12 h (A) or 24 h (B–D) with LPS (100 ng/ml). (A) SFA-exposed moDC (1 mM), CsA-exposed moDC
(1 mM) or control moDC were added to the upper chamber of the transwell and migrated to CCL19 in the lower chamber as described in Materials
and Methods. Control experiments included the spontaneous migration in the absence of CCL19. The results indicate number of migrated DC (mean
6 SEM). (B–DF) Surface CCR7 and CD38 expression of human moDCs exposed to 1 mM SFA, 1 mM CsA (B, C) or drug vehicle was analyzed by flow
cytometry with mAbs. (D) SFA but not CsA inhibits CD38 expression on matured CD1a+ moDC. The results are representative for of n=6 (A) and n=3
(B–C) independent experiments (mean 6 SEM). The results in D are representative for n=5–8 (100–500 nM SFA, CsA) and n=2 (1000 nM SFA, CsA)
independent experiments *p,0.05 ; **p,0.01 versus drug-vehicle.
doi:10.1371/journal.pone.0018406.g007
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SFA and N-Methyl-Val-4-cyclosporin (4-Cs) were provided by
Novartis Pharmaceuticals (Basel, Switzerland). Stock solutions
were prepared in absolute ethanol (vehicle) and the control DCs
were treated with drug vehicle. Dexamethasone and Cyclosporin
A were provided by Sigma-Aldrich (Seelze, Germany) and
dissolved in vehicle. The drugs were used at the indicated
concentrations and time points. The stock solutions were diluted
on the day of experiment with culture medium.
Generation of moDC
Human PBMC were isolated from buffy coats of healthy blood
donors by Ficoll-Paque (Amersham Bioscience, Uppsala, Sweden)
density gradient centrifugation. CD14
+ monocytes were purified
(.95%) using CD14 immunomagnetic microbeads (Miltenyi
Biotec, Bergisch-Gladbach, Germany) and 1610
6 cells per ml
were cultured in six-well flat-bottom plates, in 3 mL of DC
medium, comprising RPMI 1640, L-glutamine, penicillin/
streptomycin, sodium-pyruvate, hepes, nonessential amino acids,
10% heat-inactivated FCS Gold (PAA Laboratories, Linz,
Austria), 1000 IU/ml recombinant human (rh) GM-CSF (Promo
Cell, Heidelberg, Germany), and 1000 IU/ml rhIL-4 (Strathmann
Biotech GmbH, Hamburg, Germany). On day 6, CD1a
+ DC
represented .90% of cultured cells. The in vitro studies of human





+-T cells were positively selected with magnetic beads and
subsequently sorted with autoMACS (Miltenyi Biotec, Bergisch
Gladbach, Germany). Reagents were used according to the
manufacturer’s instructions. Purity of positively selected T cells
was .98% determined by flow cytometry. 1610
6 cells per ml were
cultured in six-well flat-bottom plates, in 3 mL of medium,
comprising RPMI 1640, L-glutamine, penicillin/streptomycin,
10% heat-inactivated FCS Gold (PAA Laboratories, Linz, Austria).
Figure 8. In vivo administration of SFA inhibits migration of FITC-labelled CD11c+ DCs. Mice were injected i.p. with SFA (10 mg/kg/day,
2days), CsA (10 mg/kg/day, 2 days) or vehicle. On day two, abdomen of mice were FITC-painted. The inguinal lymph nodes were removed 24 h later
and CD11c+FITC+ migrated cells quantitated by flow cytometry. (A) Dotplot analysis of CD11c+ FITC+ DCs. Numbers indicate percentages of
CD11c+FITC+ DCs. (B) Mean (6 SEM) numbers of CD11c+ FITC+ DCs in SFA-injected versus vehicle-treated controls. Results are representative for
n=3–5 independent experiments. *p,0.05 versus vehicle.
doi:10.1371/journal.pone.0018406.g008
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Analysis
On day 5, 1 mM SFA or vehicle (absolute ethanol) was added to
the DC medium. After one hour 1 mg/mL Lipopolysaccharid
(LPS, Escherichia coli 026:B6; Sigma-Aldrich, Taufkirchen, Ger-
many) was added to the culture. After 12 hours stimulation, the
RNA of 1.5610
7 cells was isolated by using the Qiagen RNeasy
Mini Kit (Hilden, Germany) according to the manufacturer’s
instructions.
The RNA from four donors was pooled and the RNA was
stored at 270uC until use. A total of n=28 donors were analyzed
by microarray. The RNA quality was confirmed with RNA 6000
Nano LabChips (Agilent Technologies, Palo Alto, USA). 1 mg
RNA was amplified with Low RNA Input Fluorescent Linear
Amplification Kit (Agilent Technologies, Palo Alto, USA) and
labeled with Cyanin 3- or Cyanin 5-CTP (Perkin Elmer, Rodgau,
Germany). cRNA of SFA and vehicle cRNA was mixed and 40 mg
cRNA was used for hybridization with whole human genome oligo
Microarray G4112A (Agilent Technologies, Palo Alto, USA). A
total number of 7 arrays were hybridized, each with a pool of
RNA from control samples and a pool of RNA from stimulated
samples (dual color with balanced between-sample dye-swap).
Hybridization and washing was done following the Agilent
protocol. Images were scanned with the Axon 4100A (Molecular
Devices, Sunnyvale, USA) and processed with GenePix 5.0. Data
analysis was done with R software version 2.10.1 (http://www.
R-project.org) using Limma [36]. Intensity values were corrected
for local background before calculation and loess normalization of
the M/A values. Genes were ranked for differential expression by
moderated t-statistics. P values were corrected for multiple testing
using the method of Bonferroni and Holm.
DC stimulation and detection of cytokine and chemokine
production by ELISA
For the chemokine expression analysis SFA, CsA and
Dexamethasone were added at day 5 for 4 hours at the indicated
concentrations. Subsequently, human moDCs were incubated at
2610
6/ml in 96-well plates in DC medium with cytokines and
stimulated for 12 h with 100 ng/ml LPS (Escherichia coli 026:B6;
Sigma-Aldrich, Taufkirchen, Germany). Phenotypic maturation of
moDC after LPS stimulation was controlled by flow cytometry
analysis of surface CD83, CD86 and MHC-II (HLA-DR)
expression (Table 2). Human CXCL10 and CXCL9 were
measured using BD OptEIA ELISA sets (BD PharMingen, San
Diego, USA). The Chemokines CCL1, CCL5, CCL17 and
CCL19 were measured using R&D Systems Developmental
DuoSets (R&D Systems, Wiesbaden-Nordenstadt, Germany)
according to the manufacturer’s instructions.
CCR7 and CD38 analysis by flow cytometry
Human moDCs were treated with SFA or vehicle at day five.
After four hours, LPS was added to the culture for additional 24 h.
The drugs were used at the indicated concentrations. Surface
staining was performed with CD1a-FITC, CD14-PE, CD38-APC
or CCR7-APC (BD Biosciences, R&D Systems) and appropriate
isotype controls (BD Biosciences, R&D Systems) according to the
manufacturer’s instructions.
In vitro migration assay
Migration was analysed by using a 24-well microchemotaxis
chamber technique with polycarbonate transwells (5 mm pore size;
Corning Costar, NY, USA) [37]. 1610
6 moDCs or CD4+ T cells
were suspended in supplemented medium. 100 ml were placed in
the upper well. moDC migrated towards 100 ng/ml CCL19 or in
other experiments human moDCs and T cells migrated towards
cell-free supernatant of SFA-exposed moDC or vehicle-treated
moDCs in the lower well. For the ‘‘SFA carry over control’’
supernatant of vehicle-treated moDC was used and spiked with
1 mM SFA. We treated human moDCs with 1 mM SFA or vehicle
for 4 hours and collected the supernatant after 12 h stimulation
with 100 ng/ml LPS. The transwells were incubated for 4 hours at
37uC in a 5% CO2 moist atmosphere. Migrated cells were
quantitated with Leukocount-Kit (BD Biosciences, San Diego,
USA) on a FACSCalibur flow cytometer (BD Biosciences, San
Jose, USA).
In vivo migration of DCs after Sanglifehrin A treatment
8–10 wk-old female C57BL/6NCrl mice were treated with SFA
or CsA (10 mg/kg/for 2 days). Drug stock solution was diluted
freshly in 2.5% Polysorbate 80, 51% PEG300 (Sigma-Aldrich) and
46.5% sterile water. On day two, the abdomen was shaved and
painted with 200 ml FITC (10 mg/ml), in a 50:50 (vol/vol)
acetone-dibutylphtahalate mixture, as described by Macatonia
et al. [28]. Inguinal lymph nodes were obtained at indicated time
points, mechanically disaggregated and passed through a cell
mesh. Cell suspensions were stained with CD11c-APC mAb and
quantitated by FACSCalibur (BD Biosciences, San Jose, USA).
Statistical analysis
Statistical analyses were performed using the Mann Whitney U
test. All tests were performed two-tailed. A probability of ,0.05
was considered significant. Analyses were performed using the
SPSS software version 16.0 (SPSS Inc, Chicago, Ill.). Microarray
results were analyzed as described above.
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